CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.3B, above the global median of $1.15B
- FinancialsAltman Z-Score 2.58: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.30BUSDvs all stocks (USD)
Revenue (TTM)
97.36MUSDvs all stocks (USD)
Profit Margin
-177.10%vs Biotechnology peers
Beta
0.8630xvs all stocks
52-Week Change
91.98%vs all stocks
Market Capitalization
1.30BUSDvs all stocks (USD)
Enterprise Value
1.03BUSDvs all stocks (USD)
Forward P/E
-4.92xvs Biotechnology peers
Price to Sales (TTM)
13.30xvs Biotechnology peers
Price to Book (MRQ)
1.98xvs Biotechnology peers
Enterprise to Revenue
10.53xvs Biotechnology peers
Enterprise to EBITDA
-5.08xvs Biotechnology peers
Profit Margin
-177.10%vs Biotechnology peers
Operating Margin
-1724.14%vs Biotechnology peers
Return on Assets (TTM)
-16.16%vs Biotechnology peers
Return on Equity (TTM)
-29.84%vs Biotechnology peers
Revenue (TTM)
97.36MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.30USDUpdated Jul 19, 2026Quarterly Revenue Growth
-86.20%vs Biotechnology peers
Gross Profit (TTM)
-148.16MUSDvs all stocks (USD)
EBITDA (TTM)
-201.80MUSDvs all stocks (USD)
Net Income (TTM)
-172.42MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-86.20%vs Biotechnology peers
Operating Cash Flow (TTM)
-186.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-76.89MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
0.00USDFY2025 · Dec 31, 2025Revenue
125.58MUSDFY2025 · Dec 31, 2025Operating Income
-177.50MUSDvs all stocks (USD)
Pre-tax Income
-89.63MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.50MUSDFY2025 · Dec 31, 2025Net Income
-92.14MUSDFY2025 · Dec 31, 2025EBIT
-57.71MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-139.54MUSDFY2025 · Dec 31, 2025Research & Development
239.43MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
63.64MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
27.52MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
31.93MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.24USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.24USDFY2025 · Dec 31, 2025Basic Shares Outstanding
74.24MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
74.24MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-92.14MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
214.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
-62.53MUSDFY2025 · Dec 31, 2025Free Cash Flow
-65.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
54.36MUSDFY2025 · Dec 31, 2025Income Tax Paid
7.31MUSDFY2025 · Dec 31, 2025Interest Paid
5.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-92.14MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
10.51MUSDFY2025 · Dec 31, 2025Stock-based Compensation
43.23MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-48.34MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
31.36MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-3.95MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.19MUSDFY2025 · Dec 31, 2025Capital Expenditures
-3.15MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-298.89MUSDFY2025 · Dec 31, 2025Sale of Investments
442.03MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
139.99MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.73MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.73MUSDFY2025 · Dec 31, 2025Shares Outstanding
74.06MSharesUpdated Jul 19, 2026Float Shares
54.42MSharesUpdated Jul 19, 2026Shares Short
11.51MSharesUpdated Jul 19, 2026Short Ratio
12.14daysvs all stocks
Short % of Shares Outstanding
22.04%vs all stocks
% Held by Insiders
1.22%vs all stocks
% Held by Institutions
115.35%vs all stocks
Total Cash (MRQ)
444.95MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.00USDUpdated Jul 19, 2026Total Debt (MRQ)
175.16MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3397xvs Biotechnology peers
Current Ratio (MRQ)
6.57xvs Biotechnology peers
Book Value per Share (MRQ)
8.84USDUpdated Jul 19, 2026Total Assets
875.50MUSDvs all stocks (USD)
Total Current Assets
599.82MUSDFY2025 · Dec 31, 2025Total Liabilities
239.91MUSDFY2025 · Dec 31, 2025Total Non-current Assets
275.67MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
144.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
95.91MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
54.07MUSDFY2025 · Dec 31, 2025Other Short-term Investments
493.66MUSDFY2025 · Dec 31, 2025Accounts Receivable
29.30MUSDFY2025 · Dec 31, 2025Accounts Payable
10.83MUSDFY2025 · Dec 31, 2025Short-term Debt
46.53MUSDFY2025 · Dec 31, 2025Long-term Debt
141.22MUSDFY2025 · Dec 31, 2025Common Stock (Book)
718.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-795.96MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
635.59MUSDvs all stocks (USD)
52-Week Low
6.92USDUpdated Jul 19, 202652-Week High
18.69USDUpdated Jul 19, 202652-Week Change
91.98%vs all stocks
Beta
0.8630xvs all stocks
50-Day MA
13.20USDUpdated Jul 19, 2026200-Day MA
13.43USDUpdated Jul 19, 2026Avg 10-Day Volume
845.96KSharesUpdated Jul 19, 2026Avg 30-Day Volume
946.21KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.29USDUpdated Jul 19, 2026Other Income / Expense
92.27MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.58: grey zoneSignificant
Altman Z-Score: 2.58
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.3B, above the global median of $1.15BNotable
Market cap (USD): 1,295,253,682Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Winsunny Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Celltrion Pharm, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinocare Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Opm Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inhibrx Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking